Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METR-NK and Solantinib in HRD+ Advanced Ovarian Cancer
NCT06884345Phase 2Active, not recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of METR-NK cells in ovarian cancer, endometrial cancer (EC), primary peritoneal carcinoma (PPC), fallopian tube cancer (PFTC), sponsored by Anhui Provincial Tumor Hospital. Started Mar 2025; status: active, not recruiting.
02
Drugs
METR-NK cells
03
Conditions
ovarian cancerendometrial cancer (EC)primary peritoneal carcinoma (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT06884345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06884345.